AVXT — AVAX Technologies Share Price
Last trade - 00:00- $0.01m
- $0.06m
- $0.62m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.02 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | -498.31% | ||
| Operating Margin | -1027.05% | ||
Financial Summary
| Year End 31st Dec | Unit | 2003 | 2004 | 2005 | 2006 | 2007 | 2008E | 2009E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.93 | 1.69 | 1.62 | 0.73 | 0.62 | n/a | n/a | -4.36% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
AVAX Technologies, Inc. is a biotechnology company. The Company is focused on developing and commercializing its Autologous Cell (AC) Vaccine Technology Platform for the treatment of cancer. The AC Vaccine is a platform technology, which allows a patient's immune system to recognize its own cancer cells as foreign through the process of haptenization, cell processing and regimen of administration. The Company has approximately two vaccines that have completed Phase II clinical trials, both designated with Orphan Drug Status. MVAX is a post-surgical autologous cell vaccine for melanoma, which was approved to enter a Phase III-REGISTRATION trial for the treatment of Stage IV melanoma patients with measurable metastasis. OVAX is the Company's post-surgical autologous cell vaccine for Stage III and IV ovarian cancer. The OVAX trial is a Phase I/II trial that has completed enrollment and is in the process of gathering follow-up data on all patients.
Directors
- John Prendergast CHM (67)
- Francois Martelet PRE (58)
- Adele Sommerfeld CEO
- Richard Rainey CAO (48)
- Andrew Dahl DRC (65)
- Edson De Castro DRC (74)
- Carl Spana DRC (59)
- Last Annual
- December 31st, 2007
- Last Interim
- September 30th, 2008
- Incorporated
- September 18th, 1992
- Public Since
- December 19th, 1996
- No. of Shareholders
- 4,000
- No. of Employees
- 29
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 142,605,753
- Address
- 2000 Hamilton St Ste 204, PHILADELPHIA, 19130-3847
- Web
- http://www.avax-tech.com/
- Phone
- +1 2152419760
- Auditors
- Briggs, Bunting & Dougherty, LLP
Similar to AVXT
Acorda Therapeutics
Pink Sheets on Nasdaq
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
FAQ
As of Today at 19:03 UTC, shares in AVAX Technologies are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in AVAX Technologies last closed at $0.00 and the price had moved by over the past 365 days. In terms of relative price strength the AVAX Technologies share price has underperformed the S&P500 Index by -11.77% over the past year.
There is no consensus recommendation for this security.
AVAX Technologies does not currently pay a dividend.
AVAX Technologies does not currently pay a dividend.
AVAX Technologies does not currently pay a dividend.
To buy shares in AVAX Technologies you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in AVAX Technologies had a market capitalisation of $0.01m.
Here are the trading details for AVAX Technologies:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: AVXT
Based on an overall assessment of its quality, value and momentum AVAX Technologies is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like AVAX Technologies. Over the past six months, its share price has outperformed the S&P500 Index by +8520.75%.
As of the last closing price of $0.00, shares in AVAX Technologies were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The AVAX Technologies PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
AVAX Technologies' management team is headed by:
- John Prendergast - CHM
- Francois Martelet - PRE
- Adele Sommerfeld - CEO
- Richard Rainey - CAO
- Andrew Dahl - DRC
- Edson De Castro - DRC
- Carl Spana - DRC